Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $33,300.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $90.00, for a total transaction of $33,300.00. Following the completion of the transaction, the director directly owned 26,671 shares of the company’s stock, valued at $2,400,390. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tempus AI Trading Down 0.7%

Shares of TEM opened at $71.56 on Friday. The company has a current ratio of 3.28, a quick ratio of 1.43 and a debt-to-equity ratio of 2.45. The stock has a market cap of $12.43 billion, a PE ratio of -60.13 and a beta of 4.86. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The stock has a 50 day simple moving average of $85.91 and a 200-day simple moving average of $70.82.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The firm had revenue of $334.21 million during the quarter, compared to analyst estimates of $328.89 million. During the same period in the prior year, the company posted ($0.46) earnings per share. The business’s revenue for the quarter was up 84.7% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TEM has been the topic of several research analyst reports. Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Canaccord Genuity Group decreased their price target on Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright cut their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Finally, Morgan Stanley raised their target price on Tempus AI from $65.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, August 12th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $79.85.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in TEM. Cranbrook Wealth Management LLC bought a new position in Tempus AI in the third quarter valued at about $25,000. Concord Wealth Partners lifted its position in Tempus AI by 308.0% during the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after purchasing an additional 308 shares during the period. GAMMA Investing LLC acquired a new position in Tempus AI during the 3rd quarter valued at about $28,000. Allworth Financial LP boosted its stake in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the last quarter. Finally, SouthState Corp raised its stake in shares of Tempus AI by 3,761.5% during the second quarter. SouthState Corp now owns 502 shares of the company’s stock worth $32,000 after buying an additional 489 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.